<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735344</url>
  </required_header>
  <id_info>
    <org_study_id>Ipca/ARL-10/385</org_study_id>
    <nct_id>NCT01735344</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition</brief_title>
  <official_title>A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IPCA Laboratories Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IPCA Laboratories Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, balanced, open Label, two-treatment, two-period, two-sequence, single
      dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence
      between Test Product and the corresponding Reference Product under fed condition in normal,
      healthy, adult, male and female human subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this pivotal study was to assess the bioequivalence between Test Product:
      Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India and the corresponding Reference
      Product: Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA, under fed
      condition in normal, healthy, adult, male and female human subjects in a randomized crossover
      study.

      The study was conducted with 40 healthy adult subjects. In each study period, a single 40 mg
      dose of either test or reference was administered to the subjects as per the randomization
      schedule in each study period with about 240 mL of water at ambient temperature in sitting
      position.

      The duration of the clinical phase was approximately 18 days including washout period of 14
      days between administrations of study drug in each study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>2 months</time_frame>
    <description>Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hrs post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>2 months</time_frame>
    <description>Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hrs post dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Fed</condition>
  <arm_group>
    <arm_group_label>Lisinopril Tablets 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zestril® (Lisinopril) 40 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril Tablets 40 mg</intervention_name>
    <description>40 mg tablet once a day</description>
    <arm_group_label>Lisinopril Tablets 40 mg</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>40 mg tablet once a day</description>
    <arm_group_label>Zestril® (Lisinopril) 40 mg Tablets</arm_group_label>
    <other_name>Zestril® (Lisinopril) 40 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and non pregnant female human subjects, age in the range of 18 - 45 years.

          2. Body weight within ± 15% of ideal weight as related to height and body frame according
             to Life Insurance Corporation (LIC) Chart.

          3. Subjects with normal findings as determined by baseline history, physical examination
             and vital sign examination (blood pressure, pulse rate, respiration rate and axillary
             temperature).

          4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry,
             urinalysis and 12 lead ECG.

          5. Willingness to follow the protocol requirements especially abstaining from xanthine
             containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit
             juice, any alcoholic products, the use of cigarettes and tobacco products for 48 hours
             prior to dosing until after the last blood sample collection in each study period and
             adherence to food, fluid and posture restrictions.

          6. No history of significant alcoholism.

          7. No history of drug abuse (benzodiazepines and barbiturates) for the last one month and
             other illegal drugs for the last 6 months.

          8. Non-smokers were included.

        Exclusion Criteria:

          1. Known history of hypersensitivity to Lisinopril or related drugs.

          2. Requiring medication for any ailment having enzyme-modifying activity in the previous
             28 days, prior to dosing day.

          3. Subjects who have taken prescription medications or over-the-counter products
             (including vitamins and minerals) within 14 days prior to administration of
             Investigational Product.

          4. Any medical or surgical conditions, which might significantly interfere with the
             functioning of gastrointestinal tract, blood-forming organs etc.

          5. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,
             metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric
             diseases.

          6. Participation in a clinical drug study or bioequivalence study 90 days prior to
             present study.

          7. History of malignancy or other serious diseases.

          8. Blood donation 90 days prior to the commencement of the study.

          9. Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.

         10. Found positive in breath alcohol test.

         11. Found positive in urine test for drug abuse.

         12. History of problem in swallowing.

         13. Any contraindication to blood sampling.

         14. Found positive serum Beta- hCG (Human Chorionic Gonadotropin) test.

         15. Lactating women (currently breast feeding).

         16. Female subjects not confirming to using birth control measures, from the date of
             screening until the completion of the study. Abstinence, barrier methods (condom,
             diaphragm, etc.) were acceptable. Use of hormonal contraceptives either oral or
             implants.

         17. Female subjects whose menstruation cycle coincided with the study periods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Suhas Khandave, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Lab (I) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accutest Research Lab (I) Pvt. Ltd.</name>
      <address>
        <city>Navi-Mumbai</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2012</study_first_submitted>
  <study_first_submitted_qc>November 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

